Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 3/20 | 0.53 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 3/20 | 0.47 |
| ▸ | KDR | P35968 | 7/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GAK | O14976 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4417741 | 0.88 | EGFR (0.53) | PDPK1ENPP1EGFRKDRCSF1R | |
| SCHEMBL24355412 | 0.87 | GAK (0.56) | PDPK1ENPP1EGFRKDRGAK | |
| SCHEMBL4417599 | 0.83 | GAK (0.53) | PDPK1ENPP1EGFRKDRGAK | |
| SCHEMBL4420286 | 0.83 | GAK (0.53) | PDPK1ENPP1EGFRKDRGAK | |
| SCHEMBL29736163 | 0.82 | KDM1A (0.57) | PDPK1EGFRKDRGAK | |
| SCHEMBL2221126 | 0.82 | KDM1A (0.57) | PDPK1EGFRKDRGAK | |
| SCHEMBL30103402 | 0.81 | PDE5A (0.57) | ENPP1EGFRKDRLMNAGLA | |
| SCHEMBL3166753 | 0.81 | PDE5A (0.57) | ENPP1EGFRKDRLMNAGLA | |
| SCHEMBL15127844 | 0.78 | ENPP1 (0.68) | ENPP1EGFRKDRCSF1RGAA | |
| SCHEMBL20285420 | 0.78 | KDM1A (0.54) | EGFRKDRGAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6806274-B1 | IMMUNOREGULATION OR IMMUNOSUPPRESSIVE AGENTS; TYROSINE KINASE INHIBITORS; PREVENTING ORGAN TRANSPLANT REJECTION; AUTOIMMUNE CONDITIONS; REDUCED SIDE EFFECTS | ASTRAZENECA UK LIMITED (GB) | 2004-10-19 | — | — | US | disclosed |
| EP-1272185-A2 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2003-01-08 | — | — | EP | disclosed |
| WO-2002002534-A1 | QUINAZOLINES WITH THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2002-01-10 | — | — | WO | disclosed |
| WO-2001066099-A2 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2001-09-13 | — | — | WO | disclosed |